MedVantx Inc., the company that created the first ever controlled access to generic samples in US physician offices, today highlighted it's MedStart Connect program as a solution to the problem specified in a recent study published in JAMA Internal Medicine. In the study, researchers reported that changes in pill color that often occur during the prescription refill process significantly increase the odds of medication non-adherence.
MedVantx, Inc., the company that pioneered a unique direct to consumer pharmaceutical distribution channel in US physician offices announced today the Company's specialty home delivery pharmacy achieved the milestone of dispensing prescriptions valued at over $600M on an annualized basis. The Company provides leading pharmaceutical manufacturers, physicians, health systems and payors novel distribution services, as well as fully transparent home delivery services to consumers nationwide via its state of the art pharmaceutical distribution facility located in Sioux Falls, SD.
The state's governor and top lawmakers are backing away from a ban on using taxpayer dollars to pay for a database that the system's supporters say is critical in combating prescription drug abuse.
Gov. Rick Scott said Tuesday he would "absolutely" support a change to state law that bans any state dollars from being spent to pay for the prescription drug database.
The U.S. Food and Drug Administration today approved Qsymia (phentermine and topiramate extended-release) as an addition to a reduced-calorie diet and exercise for chronic weight management.
The drug is approved for use in adults with a body mass index (BMI) of 30 or greater (obese) or adults with a BMI of 27 or greater (overweight) who have at least one weight-related condition such as high blood pressure (hypertension), type 2 diabetes, or high cholesterol (dyslipidemia).
On June 26, 2012, the Senate passed the final Prescription Drug User Fee Act (PDUFA) legislation, (The Food and Drug Administration (FDA) Safety and Innovation Act, S. 3187) including important provisions to mitigate drug shortages, most notably requiring manufacturers to provide advanced notification of stoppages or interruptions in production that could result in a drug shortage. The bill, which was passed by the House on Wednesday, June 20, will now go to President Obama for his signature.
EvaluatePharma, the premier provider of pharmaceutical and biotech analysis including consensus forecasts, today released its World Preview 2018 report, providing an in-depth look at how the patent cliff will reshape the drug industry over the next six years — with valuable insight into which companies and products will come out as winners.